100 related articles for article (PubMed ID: 24034915)
21. Treatment-related mortality in children with acute lymphoblastic leukemia in Central America.
Gupta S; Antillon FA; Bonilla M; Fu L; Howard SC; Ribeiro RC; Sung L
Cancer; 2011 Oct; 117(20):4788-95. PubMed ID: 21446043
[TBL] [Abstract][Full Text] [Related]
22. [Studies of childhood non-Hodgkin's lymphoma--treatment results with the CCLSG NHL 960 protocol. Children's Cancer and Leukemia Study Group (CCLSG)].
Tsurusawa M; Katano N; Hirota T; Ito M; Yanase T; Asami K; Koizumi S; Nakayama M; Miyawaki T; Suzumiya J; Nishikawa K; Mugisima H; Horikoshi Y; Hatae Y; Iwai A; Anami K; Kikuchi M; Osima K; Kaneko Y; Kataoka S; Tanaka A; Chin M; Taga T; Watanabe A; Fujimoto T
Rinsho Ketsueki; 1998 Nov; 39(11):1092-8. PubMed ID: 9866420
[TBL] [Abstract][Full Text] [Related]
23. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
Evans WE; Relling MV; Rodman JH; Crom WR; Boyett JM; Pui CH
N Engl J Med; 1998 Feb; 338(8):499-505. PubMed ID: 9468466
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
25. Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T
Int J Hematol; 1994 Feb; 59(2):99-112. PubMed ID: 8018909
[TBL] [Abstract][Full Text] [Related]
26. L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia.
Baillargeon J; Langevin AM; Lewis M; Thomas PJ; Mullins J; Dugan J; Pollock BH
Cancer; 2005 Dec; 104(12):2858-61. PubMed ID: 16288492
[TBL] [Abstract][Full Text] [Related]
27. Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia.
Yoshida H; Imamura T; Saito AM; Takahashi Y; Suenobu S; Hasegawa D; Deguchi T; Hashii Y; Kawasaki H; Endo M; Hori H; Suzuki N; Kosaka Y; Kato K; Yumura-Yagi K; Hara J; Oda M; Sato A; Horibe K;
PLoS One; 2015; 10(8):e0136428. PubMed ID: 26317422
[TBL] [Abstract][Full Text] [Related]
28. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Earl M
Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
[TBL] [Abstract][Full Text] [Related]
29. Treatment of standard-risk acute lymphoblastic leukemia in children: the results of protocol AL841 from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Okamura J; Ishii E; Ikuno Y; Koga H; Eguchi H; Yanai F; Inada H; Nibu K; Hara T; Take H; Miyazaki S; Tasaka H
Pediatr Hematol Oncol; 1999; 16(3):187-99. PubMed ID: 10326217
[TBL] [Abstract][Full Text] [Related]
30. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881.
Hutchinson RJ; Gaynon PS; Sather H; Bertolone SJ; Cooper HA; Tannous R; Wells LM; Heerema NA; Sailer S; Trigg ME;
J Clin Oncol; 2003 May; 21(9):1790-7. PubMed ID: 12721256
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.
Attarbaschi A; Morak M; Cario G; Cazzaniga G; Ensor HM; te Kronnie T; Bradtke J; Mann G; Vendramini E; Palmi C; Schwab C; Russell LJ; Schrappe M; Conter V; Mitchell CD; Strehl S; Zimmermann M; Pötschger U; Harrison CJ; Stanulla M; Panzer-Grümayer R; Haas OA; Moorman AV;
Br J Haematol; 2012 Sep; 158(6):772-7. PubMed ID: 22816614
[TBL] [Abstract][Full Text] [Related]
32. [Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)].
Kwiecińska K; Balwierz W; Moryl-Bujakowska A; Wachowiak J; Derwich K; Matysiak M; Pawelec K; Chybicka A; Dobaczewski G; Kowalczyk JR; Wiśniewska-Slusarz H; Sońta-Jakimczyk D; Szczepański T; Tomaszewska R; Wysocki M; Styczyński J; Balcerska A; Płoszyńska A
Przegl Lek; 2010; 67(6):350-4. PubMed ID: 21344760
[TBL] [Abstract][Full Text] [Related]
33. Infections during induction therapy of protocol CCLG-2008 in childhood acute lymphoblastic leukemia: a single-center experience with 256 cases in China.
Li SD; Chen YB; Li ZG; Wu RH; Qin MQ; Zhou X; Jiang J; Zhang RD; Xie J; Ma XL; Zhang R; Wang B; Wu Y; Zheng HY; Wu MY
Chin Med J (Engl); 2015 Feb; 128(4):472-6. PubMed ID: 25673448
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
[TBL] [Abstract][Full Text] [Related]
35. An update of the results of intensive therapy in children with acute lymphoblastic leukemia.
Pavlovsky S; Sackmann Muriel F; Santarelli MT; Svarch E; Jiménez E; Kohan R; Rosso A
Leukemia; 1992; 6 Suppl 2():167-70. PubMed ID: 1578923
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
[TBL] [Abstract][Full Text] [Related]
37. Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia.
Merryman R; Stevenson KE; Gostic WJ; Neuberg D; O'Brien J; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2012 Nov; 59(5):925-7. PubMed ID: 22532399
[TBL] [Abstract][Full Text] [Related]
38. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
[TBL] [Abstract][Full Text] [Related]
39. [Clinical trial of protocol-AL851 for children with high-risk acute lymphoblastic leukemia. Kyushu Yamaguchi Children's Cancer Study Group (KYCCSG)].
Matsuzaki A; Ishii E; Ueda K; Yanai F; Nibu K; Take H; Koga H; Miyazaki S; Inoue T; Miyake K
Rinsho Ketsueki; 1994 Sep; 35(9):862-70. PubMed ID: 7967055
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia].
Pan C; Gu LJ; Xue HL; Chen J; Dong L; Zhou M; Luo CY; Wang YP; Tang JY
Zhonghua Er Ke Za Zhi; 2007 May; 45(5):324-8. PubMed ID: 17697614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
